CTOs on the Move

First Environmental Labs Inc

www.firstenv.com

 
First Environmental Labs Inc is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.firstenv.com
  • 1600 Shore Rd Ste D
    Naperville, IL USA 60563
  • Phone: 630.778.1200

Executives

Name Title Contact Details

Similar Companies

Excel Dental Studios Inc

Excel Dental Studios Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Procept Biorobotics Corp

PROCEPT BioRobotics is a clinical-stage medical device company based in Silicon Valley. The Company has developed a disruptive surgical product for transurethral resection of prostate tissue – The AquaBeam® * – and other treatment and diagnostic applications. The AquaBeam is a personalized image-guided tissue removal system, which utilizes proprietary heat-free high-velocity waterjet technology to resect and remove a predetermined volume of tissue with precise and automated incisions conforming to the shape of the prostate.

Edison Imaging Associates, P.A.

Edison Imaging Associates, P.A. is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novella Clinical

Novella Clinical is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gritstone Oncology

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.